These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17148083)

  • 1. Can efavirenz be taken in the morning?
    Skeie L; Maeland A
    Scand J Infect Dis; 2006; 38(11-12):1089-91. PubMed ID: 17148083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First once-daily drug simplifies dosing, offers new options in HIV-1 treatment.
    AIDS Alert; 1998 Nov; 13(11):121-4. PubMed ID: 11365967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Protease inhibitor sparing standard. Once daily efavirenz continues to be effective].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-20. PubMed ID: 15373038
    [No Abstract]   [Full Text] [Related]  

  • 4. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
    Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
    Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efavirenz switches may be beneficial.
    AIDS Patient Care STDS; 2001 Sep; 15(9):496. PubMed ID: 11603362
    [No Abstract]   [Full Text] [Related]  

  • 6. Switching from protease inhibitors to the non-nuke efavirenz.
    TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
    [No Abstract]   [Full Text] [Related]  

  • 7. Efavirenz reclassified as FDA pregnancy category D.
    Mofenson LM
    AIDS Clin Care; 2005 Feb; 17(2):17. PubMed ID: 15754452
    [No Abstract]   [Full Text] [Related]  

  • 8. Efavirenz: enhancing the gold standard.
    Arribas JR
    Int J STD AIDS; 2003 Oct; 14 Suppl 1():6-14. PubMed ID: 14617398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA approves once-daily efavirenz formulation, revised labeling.
    AIDS Treat News; 2002 Mar; (378):7. PubMed ID: 11965921
    [No Abstract]   [Full Text] [Related]  

  • 10. Efavirenz (Sustiva).
    Res Initiat Treat Action; 2000 Mar; 6(1):22-3. PubMed ID: 11708181
    [No Abstract]   [Full Text] [Related]  

  • 11. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules.
    Portsmouth SD; Osorio J; McCormick K; Gazzard BG; Moyle GJ
    HIV Med; 2005 May; 6(3):185-90. PubMed ID: 15876285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
    Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
    J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen.
    Moyle G; Fletcher C; Brown H; Mandalia S; Gazzard B
    HIV Med; 2006 May; 7(4):243-7. PubMed ID: 16630036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sparing the protease for some spoils the price for all.
    Grinberg L
    GMHC Treat Issues; 1998 Sep; 12(9):1-2. PubMed ID: 11365802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA approves Sustiva (efavirenz) capsules, first once-daily anti-HIV drug. Food and Drug Administration.
    Res Initiat Treat Action; 1998 Oct; 4(6):13-4. PubMed ID: 11365915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
    Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
    J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitors.
    Arranz-Caso JA; Gorgolas M; Estrada V; García-Diaz JD
    HIV Med; 2004 Mar; 5(2):128-9. PubMed ID: 15012654
    [No Abstract]   [Full Text] [Related]  

  • 18. Once-daily drug for persons with HIV.
    Am Fam Physician; 1998 Dec; 58(9):2174-5. PubMed ID: 9861886
    [No Abstract]   [Full Text] [Related]  

  • 19. Experience with efavirenz in end-stage renal disease.
    Das S; Ghanem M; Huengsberg M
    Int J STD AIDS; 2004 Feb; 15(2):143. PubMed ID: 15006080
    [No Abstract]   [Full Text] [Related]  

  • 20. Options when HIV treatments fail.
    Treat Rev; 1998; (No 28):7-9. PubMed ID: 11365426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.